William D Tap1,2, Victor M Villalobos3, Gregory M Cote4, Howard Burris5, Filip Janku6, Olivier Mir7, Murali Beeram8, Andrew J Wagner9, Liewen Jiang10, Bin Wu10, Sung Choe10, Katharine Yen10, Camelia Gliser10, Bin Fan10, Sam Agresta10, Shuchi S Pandya10, Jonathan C Trent11. 1. Memorial Sloan Kettering Cancer Center, New York, NY. 2. Weill Cornell Medical College, New York, NY. 3. University of Colorado Anschutz Medical Campus, Aurora, CO. 4. Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital Cancer Center, Boston, MA. 5. Sarah Cannon Research Institute, Nashville, TN. 6. Phase I Clinical Trials Program, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX. 7. Department of Ambulatory Care, Gustave Roussy Cancer Campus, Villejuif, France. 8. START Center for Cancer Care, San Antonio, TX. 9. Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Boston, MA. 10. Agios Pharmaceuticals, Cambridge, MA. 11. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Abstract
PURPOSE: Surgery is the primary therapy for localized chondrosarcoma; for locally advanced and/or metastatic disease, no known effective systemic therapy exists. Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in up to 65% of chondrosarcomas, resulting in accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (AG-120) is a selective inhibitor of mutant IDH1 approved in the United States for specific cases of acute myeloid leukemia. We report outcomes of patients with advanced chondrosarcoma in an ongoing study exploring ivosidenib treatment. PATIENTS AND METHODS: This phase I multicenter open-label dose-escalation and expansion study of ivosidenib monotherapy enrolled patients with mutant IDH1 advanced solid tumors, including chondrosarcoma. Ivosidenib was administered orally (100 mg twice daily to 1,200 mg once daily) in continuous 28-day cycles. Responses were assessed every other cycle using RECIST (version 1.1). RESULTS: Twenty-one patients (escalation, n = 12; expansion, n = 9) with advanced chondrosarcoma received ivosidenib (women, n = 8; median age, 55 years; range, 30-88 years; 11 had received prior systemic therapy). Treatment-emergent adverse events (AEs) were mostly grade 1 or 2. Twelve patients experienced grade ≥ 3 AEs; only one event was judged treatment related (hypophosphatemia, n = 1). Plasma 2-HG levels decreased substantially in all patients (range, 14%-94.2%), to levels seen in healthy individuals. Median progression-free survival (PFS) was 5.6 months (95% CI, 1.9 to 7.4 months); the PFS rate at 6 months was 39.5%. Eleven (52%) of 21 patients experienced stable disease. CONCLUSION: In patients with chondrosarcoma, ivosidenib showed minimal toxicity, substantial 2-HG reduction, and durable disease control. Future studies of ivosidenib monotherapy or rational combination approaches should be considered in patients with advanced mutant IDH1 chondrosarcoma.
PURPOSE: Surgery is the primary therapy for localized chondrosarcoma; for locally advanced and/or metastatic disease, no known effective systemic therapy exists. Mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) enzymes occur in up to 65% of chondrosarcomas, resulting in accumulation of the oncometabolite D-2-hydroxyglutarate (2-HG). Ivosidenib (AG-120) is a selective inhibitor of mutant IDH1 approved in the United States for specific cases of acute myeloid leukemia. We report outcomes of patients with advanced chondrosarcoma in an ongoing study exploring ivosidenib treatment. PATIENTS AND METHODS: This phase I multicenter open-label dose-escalation and expansion study of ivosidenib monotherapy enrolled patients with mutant IDH1 advanced solid tumors, including chondrosarcoma. Ivosidenib was administered orally (100 mg twice daily to 1,200 mg once daily) in continuous 28-day cycles. Responses were assessed every other cycle using RECIST (version 1.1). RESULTS: Twenty-one patients (escalation, n = 12; expansion, n = 9) with advanced chondrosarcoma received ivosidenib (women, n = 8; median age, 55 years; range, 30-88 years; 11 had received prior systemic therapy). Treatment-emergent adverse events (AEs) were mostly grade 1 or 2. Twelve patients experienced grade ≥ 3 AEs; only one event was judged treatment related (hypophosphatemia, n = 1). Plasma 2-HG levels decreased substantially in all patients (range, 14%-94.2%), to levels seen in healthy individuals. Median progression-free survival (PFS) was 5.6 months (95% CI, 1.9 to 7.4 months); the PFS rate at 6 months was 39.5%. Eleven (52%) of 21 patients experienced stable disease. CONCLUSION: In patients with chondrosarcoma, ivosidenib showed minimal toxicity, substantial 2-HG reduction, and durable disease control. Future studies of ivosidenib monotherapy or rational combination approaches should be considered in patients with advanced mutant IDH1 chondrosarcoma.
Authors: Suzan H M Verdegaal; Judith V M G Bovée; Twinkal C Pansuriya; Robert J Grimer; Harzem Ozger; Paul C Jutte; Mikel San Julian; David J Biau; Ingrid C M van der Geest; Andreas Leithner; Arne Streitbürger; Frank M Klenke; Francois G Gouin; Domenico A Campanacci; Perrine Marec-Berard; Pancras C W Hogendoorn; Ronald Brand; Antonie H M Taminiau Journal: Oncologist Date: 2011-12-06
Authors: Rasheduzzaman Chowdhury; Kar Kheng Yeoh; Ya-Min Tian; Lars Hillringhaus; Eleanor A Bagg; Nathan R Rose; Ivanhoe K H Leung; Xuan S Li; Esther C Y Woon; Ming Yang; Michael A McDonough; Oliver N King; Ian J Clifton; Robert J Klose; Timothy D W Claridge; Peter J Ratcliffe; Christopher J Schofield; Akane Kawamura Journal: EMBO Rep Date: 2011-04-01 Impact factor: 8.807
Authors: Robert S Benjamin; Haesun Choi; Homer A Macapinlac; Michael A Burgess; Shreyaskumar R Patel; Lei L Chen; Donald A Podoloff; Chuslip Charnsangavej Journal: J Clin Oncol Date: 2007-05-01 Impact factor: 44.544
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Annemiek van Maldegem; Anthony P Conley; Piotr Rutkowski; Shreyaskumar R Patel; Iwona Lugowska; Ingrid M E Desar; Judith V M G Bovée; Hans Gelderblom Journal: Oncologist Date: 2018-08-06
Authors: A Italiano; A Le Cesne; C Bellera; S Piperno-Neumann; F Duffaud; N Penel; P Cassier; J Domont; N Takebe; M Kind; J-M Coindre; J-Y Blay; B Bui Journal: Ann Oncol Date: 2013-11 Impact factor: 32.976
Authors: Darrell R Borger; Kenneth K Tanabe; Kenneth C Fan; Hector U Lopez; Valeria R Fantin; Kimberly S Straley; David P Schenkein; Aram F Hezel; Marek Ancukiewicz; Hannah M Liebman; Eunice L Kwak; Jeffrey W Clark; David P Ryan; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Andrew X Zhu; A John Iafrate Journal: Oncologist Date: 2011-12-16 Impact factor: 5.837
Authors: Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick Journal: Cancer Cell Date: 2010-12-09 Impact factor: 38.585
Authors: Hai Yan; D Williams Parsons; Genglin Jin; Roger McLendon; B Ahmed Rasheed; Weishi Yuan; Ivan Kos; Ines Batinic-Haberle; Siân Jones; Gregory J Riggins; Henry Friedman; Allan Friedman; David Reardon; James Herndon; Kenneth W Kinzler; Victor E Velculescu; Bert Vogelstein; Darell D Bigner Journal: N Engl J Med Date: 2009-02-19 Impact factor: 176.079
Authors: Morten Lapin; Helen J Huang; Sharmeen Chagani; Milind Javle; Rachna T Shroff; Shubham Pant; Mohamed A Gouda; Anjali Raina; Kiran Madwani; Veronica R Holley; S Greg Call; Derek J Dustin; Richard B Lanman; Funda Meric-Bernstam; Victoria M Raymond; Lawrence N Kwong; Filip Janku Journal: JCO Precis Oncol Date: 2022-02
Authors: Tahir N Sheikh; Xiao Chen; Xinjing Xu; John T McGuire; Matthew Ingham; Chao Lu; Gary K Schwartz Journal: Mol Cancer Ther Date: 2021-09-22 Impact factor: 6.009
Authors: Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639
Authors: Mohammed Khurshed; Remco J Molenaar; Myra E van Linde; Ron A Mathôt; Eduard A Struys; Tom van Wezel; Cornelis J F van Noorden; Heinz-Josef Klümpen; Judith V M G Bovée; Johanna W Wilmink Journal: Cancers (Basel) Date: 2021-05-19 Impact factor: 6.639
Authors: Benjamin A Nacev; Kevin B Jones; Andrew M Intlekofer; Jamie S E Yu; C David Allis; William D Tap; Marc Ladanyi; Torsten O Nielsen Journal: Nat Rev Cancer Date: 2020-08-11 Impact factor: 69.800